Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dextenza for pain and inflammation in patients receiving anti-VEGF injections
NCT04563299Phase 4Terminated
- Sponsor
- Retina Vitreous Associates of Florida
- Start
- Dec 2020
- Primary completion
- Feb 2023
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ozurdex in pain, ocular inflammation, sponsored by Retina Vitreous Associates of Florida. Started Dec 2020; status: terminated.
02
Drugs
ozurdex
03
Conditions
painocular inflammation
Beyond the preview
Go deeper on NCT04563299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04563299.